Innovate Biopharmaceuticals Inc. (INNT) and Mersana Therapeutics Inc. (NASDAQ:MRSN) Comparing side by side

We will be contrasting the differences between Innovate Biopharmaceuticals Inc. (NASDAQ:INNT) and Mersana Therapeutics Inc. (NASDAQ:MRSN) as far as institutional ownership, profitability, analyst recommendations, risk, dividends, earnings and valuation are concerned. The two businesses are rivals in the Biotechnology industry.

Earnings & Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Innovate Biopharmaceuticals Inc. N/A 0.00 13.64M -1.07 0.00
Mersana Therapeutics Inc. 48.56M 3.77 29.95M -2.79 0.00

Table 1 demonstrates Innovate Biopharmaceuticals Inc. and Mersana Therapeutics Inc.’s gross revenue, earnings per share and valuation.


Table 2 demonstrates the return on equity, return on assets and net margins of Innovate Biopharmaceuticals Inc. and Mersana Therapeutics Inc.

Net Margins Return on Equity Return on Assets
Innovate Biopharmaceuticals Inc. 0.00% 0% -245.4%
Mersana Therapeutics Inc. -61.68% -57.5% -27.9%

Institutional & Insider Ownership

Institutional investors owned 10.7% of Innovate Biopharmaceuticals Inc. shares and 59.9% of Mersana Therapeutics Inc. shares. About 0.1% of Innovate Biopharmaceuticals Inc.’s share are owned by insiders.


In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Innovate Biopharmaceuticals Inc. 2.61% -15.59% -28.31% -59.11% -89.81% -32.03%
Mersana Therapeutics Inc. 7.14% 27.93% -5.51% -2.12% -63.66% 47.06%

For the past year Innovate Biopharmaceuticals Inc. has -32.03% weaker performance while Mersana Therapeutics Inc. has 47.06% stronger performance.


On 5 of the 9 factors Mersana Therapeutics Inc. beats Innovate Biopharmaceuticals Inc.

Innovate Biopharmaceuticals, Inc., a clinical stage biotechnology company, focuses on developing autoimmune and inflammation therapeutics. Its late-stage clinical pipeline focuses on addressing unmet needs in diseases, such as celiac disease, inflammatory bowel disease (IBD), and nonalcoholic steatohepatitis (NASH). The company's lead drug candidate, larazotide acetate (INN-202), has successfully met its primary endpoint in a Phase 2b efficacy clinical trial for celiac disease. It is also developing INN-108, which is entering into Phase 2 clinical trials for the treatment of mild to moderate ulcerative colitis. In addition, the company owns the global rights to INN-329, a proprietary formulation of secretin, a peptide hormone used to enhance visualization in magnetic resonance cholangiopancreatography procedures. Innovate Biopharmaceuticals, Inc. was founded in 2012 and is based in Raleigh, North Carolina.

Mersana Therapeutics, Inc. is a biotechnology company that discovers, engineers, and develops antibody drug conjugates to cure various cancers. The company develops immune conjugate therapies to create drugs that enhance patientsÂ’ lives. It offers XMT-1522, a drug therapy for tumor models that express relatively low amounts of the HER2 protein; and human anti-HER2 antibody used in XMT-1522. Mersana Therapeutics, Inc. has strategic alliances with Takeda Pharmaceutical Company Limited; Merck Serono; and Asana BioSciences. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005. Mersana Therapeutics, Inc. was founded in 2001 and is based in Cambridge, Massachusetts.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.